Nous Defions, LLC
USPTO PatentsView assignee record - 7 granted patents across 2 technology areas, recorded in grant years 2017–2019. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: F41C (Smallarms, e.g. Pistols, Rifles ; Accessories Therefor).
The verdict
According to USPTO PatentsView, Nous ranks #36,737 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 2 technology areas.
- #36,737
- of 49,997 US assignees by volume
- 3rd percentile
- by Innovation Score (15.3/100)
- 5.3
- avg claims per patent
- -100%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R36737 · US Corporation #36,737 · 7 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-LOW · CLAIMS-SPARSE · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 7 grants
- MID-PACK #36,737/49,997
- PHOTO-FINISH Northstar Medical
- CPC-NARROW F41C · 2 areas
- INNOV-LOW 15.3/100
- CLAIMS-SPARSE 5.3 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -100% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Northstar Medical Technologies LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Nous’s 15.3 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Nous
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Nous Defions · this assignee 15
Nous Defions · this assignee
15 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Nous's Innovation Score is 15.3/100 (3rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Nous?
Each dot is one of Nous’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Nous’s own 5.3 claims/patent is at or below the 18.1 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Nous's grants concentrate
Nous Defions, LLC is a focused PatentsView assignee: 2 CPC subclasses with 28.6% of grants classified under F41C (Smallarms, e.g. Pistols, Rifles ; Accessories Therefor). Peak complete grant year is 2017 (3 grants) versus a trough of 2 in 2018. By volume, Nous sits between Northstar Medical Technologies LLC and Novvi LLC.
Who files at Nous's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Northstar Medical
Northstar Medical Technologies LLC
7 patents
- Notion AI
Notion AI, Inc.
7 patents
- Notion Labs
Notion Labs, Inc.
7 patents
- Nottingham Spirk…
Nottingham Spirk Design Associates
7 patents
- Novaplast
Novaplast Corporation
7 patents
- Novar ED&S
Novar ED&S Limited
7 patents
- Novomedix
NovoMedix, LLC
7 patents
- Novvi
Novvi LLC
7 patents
- Nous Defions ◀
Nous Defions, LLC
7 patents
What this shows Nous holds 7 patents at rank #36,736, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Nous
By rank, the assignees closest to #36,736 in granted patent volume.
- Northstar Medical Technologies LLC #36,732 · 7 patents
- Notion AI, Inc. #36,733 · 7 patents
- Notion Labs, Inc. #36,734 · 7 patents
- Nottingham Spirk Design Associates #36,735 · 7 patents
- Novaplast Corporation #36,737 · 7 patents
- Novar ED&S Limited #36,738 · 7 patents
- NovoMedix, LLC #36,739 · 7 patents
- Novvi LLC #36,740 · 7 patents
Leaders in F41C (Smallarms)
Other assignees with the most granted patents in Nous's primary technology class.
Nous's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
15 3rd percentile higher than 3% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 3 | 42.9% |
| 2018 | 2 | 28.6% |
| 2019 | 2 | 28.6% |
Which technologies does Nous Defions, LLC patent most?
Top 2 of 2 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Nous Defions, LLC's patent record in context - here's where to go next.
- Nous Defions, LLC's lead technology class is F41C (Smallarms, e.g. Pistols, Rifles ; Accessories Therefor), 28.6% of its portfolio - see every assignee active in that class. Explore F41C
- Ranked #36,737 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Nous Defions, LLC against Northstar Medical Technologies LLC, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 15.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.